TAK-ATAC

TAK-ATAC is an investigational antibody-targeted amanitin conjugate (ATAC) being developed by Takeda in collaboration with Heidelberg Pharma. It utilizes Heidelberg Pharma's proprietary ATAC technology, which conjugates a monoclonal antibody to amanitin, a cytotoxic payload derived from the death cap mushroom (*Amanita phalloides*). Amanitin's mechanism of action involves the potent inhibition of RNA polymerase II, leading to the cessation of transcription and subsequent apoptosis in target cells. This mechanism is particularly effective against both dividing and quiescent cells, potentially overcoming resistance to traditional microtubule-inhibiting or DNA-damaging ADC payloads. The specific antibody target remains undisclosed, but the candidate is currently being evaluated in Phase I/II clinical trials for the treatment of various solid tumors.

Other names

TAK-ATAC-Heidelberg Pharma-ATAC-OncologyTakeda ATAC candidateHeidelberg Pharma ATAC